Every cell type we create can give rise to multiple next generation therapies

The third generation of medicine is intelligent



Every cell, every patient

The revolutionary impact of cell therapies has already become apparent: engineered CAR-T cells are able to cure blood cancers that used to be untreatable. The application of one single cell type sparked the first wave of cell therapy companies. 

bit.bio is working to generalise this approach across the whole spectrum of human cell types, and to make it accessible.

We are building a therapeutic pipeline across three key focus areas: liver, immunology and metabolic. And we are working with partners to leverage our platform to discover and develop new cell types for therapies. We believe the possibilities for novel cures are endless. 

Solving the ‘cell’ problem in cell therapy

The biggest hurdle in cell therapy today is access to consistent batches of human cell types at scale. 

Therapeutic development needs trillions of cells at an affordable cost in order to generate medicines that are accessible to millions of patients.

bit.bio’s cell identity coding platform is able to create new defined human cell types that are inherently consistent and scalable. Our approach has the potential to reduce the cost of cell therapies by up to two orders of magnitude.  

Solving the 'cell' problem with our cell identity coding platform

Discovery of cell identity

We integrate machine learning, big data and large scale experimentation to identify the optimal set of transcription factors that drive the reprogramming of human iPSCs into human cells with defined therapeutic functionality. 

Precision reprogramming technology

opti-ox™ ensures the robust, safe and precise reprogramming of human iPSCs into a desired cell type, allowing consistent manufacture at scale. 

World-leading expertise

Our cell identity coding platform combines leading experts in stem cell reprogramming, manufacturing and clinical translation. 


Partner with us to develop human cells for your cell therapeutics

Therapeutic development and manufacture needs to scale to trillions of cells to generate enough doses of a therapy that can be deployed to millions of patients.

Our platform provides partners with the ability to create new, inherently consistent and scalable cell types to form the basis of a cell therapy. By solving the cell problem, our partners are enabled to shift focus from “How are we going to make enough cells to treat one patient?” to "How can we ensure our therapeutic can treat every patient?".


Collaboration and option agreement with BlueRock Therapeutics

In August 2023, bit.bio announced a collaboration and option agreement with BlueRock Therapeutics for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics.

Tregs play a crucial role in maintaining balance in the body’s immune system and controlling excessive immune reactions so iPSC-derived Treg based therapies have the potential to treat a broad range of autoimmune and inflammatory disorders.


Related pages

Discover ioCells Learn about our range of human iPSC-derived cells for research and drug discovery
Our platform Discover the cell identity coding platform behind our cells
About us Find out more about us and our people